Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
ACRSAclaris Therapeutics(ACRS) ZACKS·2024-08-07 21:16

Aclaris Therapeutics (ACRS) came out with a quarterly loss of 0.15pershareversustheZacksConsensusEstimateofalossof0.15 per share versus the Zacks Consensus Estimate of a loss of 0.19. This compares to loss of 0.42pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof21.050.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.05%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of 0.28 per share when it actually produced a loss of $0.24, delivering a surprise of 14.29%.Over the last four quar ...